[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2015092810A3 - Amorphous form of idelalisib - Google Patents

Amorphous form of idelalisib Download PDF

Info

Publication number
WO2015092810A3
WO2015092810A3 PCT/IN2014/000724 IN2014000724W WO2015092810A3 WO 2015092810 A3 WO2015092810 A3 WO 2015092810A3 IN 2014000724 W IN2014000724 W IN 2014000724W WO 2015092810 A3 WO2015092810 A3 WO 2015092810A3
Authority
WO
WIPO (PCT)
Prior art keywords
amorphous form
idelalisib
relates
processes
preparation
Prior art date
Application number
PCT/IN2014/000724
Other languages
French (fr)
Other versions
WO2015092810A2 (en
Inventor
Shriprakash Dhar DWIVEDI
Brij Khera
Kumar Kamlesh SINGH
Nikhil Amar SINGH
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Publication of WO2015092810A2 publication Critical patent/WO2015092810A2/en
Publication of WO2015092810A3 publication Critical patent/WO2015092810A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to an amorphous form of idelalisib and processes for the preparation of the amorphous form. The invention also relates to pharmaceutical compositions that include the amorphous form of idelalisib
PCT/IN2014/000724 2013-11-20 2014-11-19 Amorphous form of idelalisib WO2015092810A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3641/MUM/2013 2013-11-20
IN3641MU2013 IN2013MU03641A (en) 2013-11-20 2014-11-19

Publications (2)

Publication Number Publication Date
WO2015092810A2 WO2015092810A2 (en) 2015-06-25
WO2015092810A3 true WO2015092810A3 (en) 2015-08-13

Family

ID=52785145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000724 WO2015092810A2 (en) 2013-11-20 2014-11-19 Amorphous form of idelalisib

Country Status (2)

Country Link
IN (1) IN2013MU03641A (en)
WO (1) WO2015092810A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016097314A1 (en) * 2014-12-19 2016-06-23 Sandoz Ag Amorphous and crystalline forms of idelalisib and process for forming the same
US20180064714A1 (en) * 2015-03-13 2018-03-08 Mylan Laboratories Ltd Process for the Preparation of Amorphous Idelalisib and its Premix
WO2016157136A1 (en) 2015-04-02 2016-10-06 Mylan Laboratories Ltd Crystalline forms of idelalisib
CN104892612B (en) * 2015-04-15 2017-12-19 上海方楠生物科技有限公司 A kind of Ai Delibu amorphous article and preparation method thereof
WO2017137097A1 (en) * 2016-02-12 2017-08-17 Synthon B.V. Pharmaceutical composition comprising idelalisib in amorphous form
WO2017175184A1 (en) * 2016-04-07 2017-10-12 Laurus Labs Limited Process for preparation of amorphous form of idelalisib
EP3272348A1 (en) 2016-07-21 2018-01-24 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising idelalisib
WO2019178596A1 (en) 2018-03-16 2019-09-19 Johnson Matthey Public Limited Company Pyridine or n,n-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113556A1 (en) * 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2013134288A1 (en) * 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113556A1 (en) * 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2013134288A1 (en) * 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one

Also Published As

Publication number Publication date
IN2013MU03641A (en) 2015-07-31
WO2015092810A2 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
WO2016011306A3 (en) Terminal modifications of polynucleotides
WO2015085318A3 (en) Targeted adaptive vaccines
PH12016501122A1 (en) Delayed release compositions of linaclotide
WO2015092810A3 (en) Amorphous form of idelalisib
WO2015081257A3 (en) Aminopyridine derivatives as tam family kinase inhibitors
EP2991658A4 (en) Antimicrobial compositions and methods of making the same
EP3021843A4 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
EP3068500A4 (en) Fertilizer compositions and methods of making and using the same
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2016009401A3 (en) Preparation of tedizolid phosphate
WO2015029074A3 (en) Compositions of eltrombopag
HK1208378A1 (en) Pharmaceutical composition for the treatment of fungal infections
WO2013164839A8 (en) Amorphous form of apixaban, process of preparation and compositions thereof
IL243435B (en) High potery pancreatin pharmaceutical compositions
EP3642415A4 (en) Nanolignocellulose compositions and processes to produce these compositions
WO2016001885A3 (en) Amorphous form of eliglustat hemitartarate
EP3003324A4 (en) Pharmaceutical compositions
EP3288636A4 (en) Compositions for the treatment of epistaxis
EP3016935A4 (en) Process for the preparation of intermediate of dolutegravir
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
WO2014133811A3 (en) Compounds from invasive salvinias and methods of using the same
MX2015016603A (en) Corticosteroid compositions.
WO2015044434A3 (en) Fluor-9-methyl-β-carbolines
WO2014128728A3 (en) Solid forms of cabazitaxel and processes for preparation thereof
WO2015108945A3 (en) Compositions and methods for the delivery of therapeutics

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14851422

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14851422

Country of ref document: EP

Kind code of ref document: A2